Elotuzumab (Elo) is a humanized IgG1 mAb targeting SLAMF7, and Elo‐based combination therapies have demonstrated significant clinical activity in relapsed/refractory MM.52 Here, SLAMF7 is linked to Miyoshi myopathy.